Puma Biotechnology Inc. (PBYI) announced after the close Wednesday that its Phase 3 study of neratinib, a breast cancer treatment, improved disease-free survival for certain patients by 2.3 months.
Puma Biotechnology gapped open sharply lower Thursday and slipped further in early trade, before settling into a range. The stock closed down by 39.05 at $170.67, with volume at nearly a 10-month high. Puma Biotechnology closed testing the lower end of over a 2-week trading range.
For comments and feedback contact: editorial@rttnews.com
Business News